Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib

Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen

Melissa Hopper - Immunology Doctoral Candidate - Mayo Clinic Graduate School of Biomedical Sciences

Covalent Modifiers: 2017

Development of covalent inhibitors: Principle, design, and application in cancer - Zheng - 2023 - MedComm – Oncology - Wiley Online Library

Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

A Perspective on the Kinetics of Covalent and Irreversible Inhibition

Frontiers Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

Kinetic mechanisms of covalent inhibition - ScienceDirect

Case Study - COVALfinder to Study Irreversible EGFR Drugs

A steady-state algebraic model for the time course of covalent enzyme inhibition

Full article: Drug delivery targets and strategies to address mast cell diseases

Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors - RSC Chemical Biology (RSC Publishing) DOI:10.1039/D0CB00033G

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. - Abstract - Europe PMC

Covalent Modifiers: 2017

Proteomics and Beyond: Cell Decision-Making Shaped by Reactive Electrophiles: Trends in Biochemical Sciences